Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NAMS 
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: NAMS (5-star) is a STRONG-BUY. BUY since 103 days. Simulated Profits (85.95%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $41.71
1 Year Target Price $41.71
| 5 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 200.41% | Avg. Invested days 51 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.11B USD | Price to earnings Ratio - | 1Y Target Price 41.71 |
Price to earnings Ratio - | 1Y Target Price 41.71 | ||
Volume (30-day avg) 9 | Beta 0.06 | 52 Weeks Range 14.06 - 41.47 | Updated Date 11/5/2025 |
52 Weeks Range 14.06 - 41.47 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -258.91% | Operating Margin (TTM) -186.13% |
Management Effectiveness
Return on Assets (TTM) -17.12% | Return on Equity (TTM) -28.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2718859660 | Price to Sales(TTM) 64.28 |
Enterprise Value 2718859660 | Price to Sales(TTM) 64.28 | ||
Enterprise Value to Revenue 42.48 | Enterprise Value to EBITDA 27.63 | Shares Outstanding 112628458 | Shares Floating 56140781 |
Shares Outstanding 112628458 | Shares Floating 56140781 | ||
Percent Insiders 0.39 | Percent Institutions 109.27 |
Upturn AI SWOT
NewAmsterdam Pharma Company N.V. Ordinary Shares
Company Overview
History and Background
NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, once-daily therapies for patients at high risk of cardiovascular disease with high triglycerides. Founded in 2019.
Core Business Areas
- Lipid Metabolism: Development and commercialization of therapies targeting lipid metabolism pathways.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical development and commercialization.
Top Products and Market Share
Key Offerings
- Obicetrapib: Obicetrapib is an oral cholesteryl ester transfer protein (CETP) inhibitor being developed to lower LDL-C and reduce cardiovascular risk. Currently in Phase 3 trials. Competitors include statins, PCSK9 inhibitors, and other emerging therapies targeting lipid metabolism.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with significant investment in research and development. The market for cardiovascular disease therapies is large and growing, driven by aging populations and increasing prevalence of risk factors.
Positioning
NewAmsterdam Pharma is positioning itself as a leader in developing novel therapies for cardiovascular disease, particularly targeting lipid metabolism pathways. The company's competitive advantage lies in its oral CETP inhibitor, Obicetrapib.
Total Addressable Market (TAM)
The total addressable market for cardiovascular disease therapies is estimated to be in the tens of billions of dollars. NewAmsterdam Pharma is positioning itself to capture a significant share of this market with Obicetrapib.
Upturn SWOT Analysis
Strengths
- Novel CETP inhibitor
- Oral, once-daily administration
- Phase 3 clinical trials underway
- Experienced management team
Weaknesses
- Dependence on a single product candidate
- Clinical trial risks
- Competition from established therapies
- Relatively new company
Opportunities
- Large and growing market for cardiovascular disease therapies
- Potential to address unmet medical need
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Pricing pressures
Competitors and Market Share
Key Competitors
- AMGN
- REGN
- MRK
- PFE
Competitive Landscape
NewAmsterdam Pharma faces intense competition from established pharmaceutical companies with existing cardiovascular disease therapies. The company's success will depend on demonstrating the superior efficacy and safety of Obicetrapib.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable for a company in the clinical stage.
Future Projections: Future growth is dependent on the successful development and commercialization of Obicetrapib. Analyst estimates vary depending on the perceived probability of success.
Recent Initiatives: Focus on advancing Obicetrapib through Phase 3 clinical trials and preparing for potential commercialization.
Summary
NewAmsterdam Pharma is a clinical-stage company focused on developing Obicetrapib, a novel CETP inhibitor for cardiovascular disease. The company's success hinges on positive Phase 3 trial results and regulatory approval. While it faces competition from established players, Obicetrapib has the potential to address unmet medical needs. Financial stability depends on securing future funding. The company needs to manage clinical trial risks and navigate the regulatory landscape successfully.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewAmsterdam Pharma Company N.V. Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-11-23 | CEO, President & Executive Board Member Dr. Michael Harvey Davidson FACC, Facp., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 68 | |
Full time employees 68 | |||
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.